Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study.

Pakdaman, Hossein; Gharagozli, Koroush; Abbasi, Mehdi; Sobhanian, Ali; Bakhshandehpour, Ali; Ashrafi, Farzad; Khalilzad, Mitra; Amini Harandi, Ali

Pakdaman, Hossein; Gharagozli, Koroush; Abbasi, Mehdi; Sobhanian, Ali; Bakhshandehpour, Ali; Ashrafi, Farzad; Khalilzad, Mitra; Amini Harandi, Ali.

Afiliação

Pakdaman H; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gharagozli K; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abbasi M; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sobhanian A; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Bakhshandehpour A; Health and Human Physiology School, University of Iowa, Iowa City, Iowa, USA.
Ashrafi F; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Khalilzad M; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amini Harandi A; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Dement Geriatr Cogn Dis Extra ; 8(1): 174-179, 2018.

Article em En | MEDLINE | ID: mdl-29805383

Palavras-chave

Alzheimer disease; Follow-up study; MLC601; Safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Dement Geriatr Cogn Dis Extra Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Irã

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google